Showing results (111-120 of 437) with videos related to
Sort By:
Pageof 44
Ophthalmology and Therapy|September 13, 2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.Blood Cancer Journal|November 27, 2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneTimothy M Schmidt, Benjamin G Barwick, Nisha Joseph, et al.Nature Communications|March 8, 2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myelomaRicha Bajpai, Aditi Sharma, Abhinav Achreja, et al.JCI Insight|April 24, 2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathyJithendra Kini Bailur, Samuel S McCachren, Deon B Doxie, et al.Ophthalmology and Therapy|July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.British Journal of Haematology|February 29, 2024
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, et al.Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.Cancer Biology & Therapy|September 26, 2003
Signal transduction and myeloma: new targets, new hopeSagar Lonial, Edmund K Waller, Jonathan W Simons, et al.Science Advances|September 28, 2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myelomaAditi Sharma, Remya Nair, Abhinav Achreja, et al.Pageof 44